Factors affecting prognosis in signet ring cell gastric cancers with expanded lymph node dissection; high volume centre experience

Serdar Culcu*, Selim Tamam, Ali Ekrem Unal

ABSTRACT

Background: Signet ring cell gastric cancer differs from gastric adenocarcinoma in terms of demographic and clinical features, age, gender, tumour grade and stage. In this study, we aimed to evaluate the clinical features and overall survival of gastric signet ring cell carcinoma and the prognostic factors affecting survival.

Methods: We analysed 138 patients who were operated on with the diagnosis of signet ring cell gastric cancer. The univariant and multivariate hazard ratios of these parameters were analysed and the factors affecting the long-term average survival outcomes were investigated.

Results: We performed Cox regression univariate analysis to investigate the effects of clinicopathological factors on mean survival follow-up in signet ring cell gastric cancer. As age increases, the mean survival follow-up period decreases. This relationship is also statistically significant. Mean survival follow-up for the open technique was lower than for laparoscopic procedures. The mean survival follow-up time of patients with positive perineural invasion (PNI) and lymphovascular invasion (LVI) is lower than patients with negative LVI and PNI. We did not find a significant relationship between the hazard ratios (HRs) of tumour markers and systemic inflammatory response parameters. However, we found a significant relationship between the increase in fibrinogen value and HR.

Conclusions: We investigated the clinicopathological features of nonmetastatic signet ring cell gastric carcinomas and identified predictors of long survival. Age, lymphovascular and perineural invasion, open surgery, higher tumor infiltration, and lymph node involvement were independent predictors of shorter survival times in nonmetastatic signet ring cell gastric cancers.

Keywords: Gastric cancer, Signet ring cell carcinoma, Gastrectomy

INTRODUCTION

Although gastric cancer survival outcomes have improved significantly in recent years, it is one of the most common causes of cancer-related deaths worldwide.\(^1\) Histopathologically, the most common type is adenocarcinoma.\(^2\) The 2019 World Health Organization (WHO) classification has divided gastric adenocarcinomas into five main groups: tubular, papillary, mucinous, poorly cohesive, and mixed adenocarcinoma. The incidence of signet ring cell carcinoma, which is a subtype of poorly cohesive carcinomas and accounts for 16.8% of gastric cancer cases, has been increasing in recent years.\(^3\) It is a rare histological type with a poor prognosis due to rapid tumor growth and infiltration into surrounding tissues.\(^4\) With the developments in treatment modalities, its prognosis tends to improve in recent years.\(^5\)

Signet ring cell carcinoma is a histological diagnosis characterized by prominent cytoplasmic mucin expression and a nucleus pushed to the periphery.\(^6\) It exhibits different tumorigenic properties and epidemiological distribution compared to other types of gastric cancer.\(^7\) It differs from...
gastric adenocarcinoma in terms of demographic and clinical features, age, gender, tumor grade, and stage.\(^3\)

Although there are studies on the prognostic values of various factors in gastric cancer in the literature, data on prognostic factors in signet ring cell cancers are limited.\(^4\)

Today, the American Joint Cancer Committee (AJCC) staging system is used to evaluate gastric cancer prognosis and treatment plan.\(^5\) However, since the AJCC staging system does not take into account some important clinicopathological features such as age, gender, and treatment method when patients are evaluated individually, it may not be sufficient to predict survival.\(^9\)

However, due to their rarity, data on optimal treatment management are limited. Therefore, investigating the specific characteristics of patients can provide the necessary information to improve the clinical management of these patients. In this study, we aimed to evaluate the clinical features and overall survival of gastric signet ring cell carcinoma and the prognostic factors affecting survival.

**METHODS**

We retrospectively analysed 138 patients who were operated on with the diagnosis of signet ring cell gastric cancer in the department of surgical oncology, Faculty of Medicine, Ankara University, between 2006 and 2018. Because the study was retrospective, ethical approval was not obtained.

To be considered signet ring cell (SRC), more than 50% mucin and cohesive variants in the pathology reports were found. Patients with >50% mucin and a component containing cohesive variants in their endoscopic pathology or final pathology and without distant metastases in their preoperative imaging were included in the study. Patients with distant metastases, synchronous tumors, and signet ring component <50% were excluded from the study. 2 patients with recurrence, 4 patients with peritoneal involvement, and 4 patients with missing parameters in the file examination were excluded from the study. A total of 128 patients were included in the study. Since the factors affecting the mean survival of signet ring cell gastric cancer were investigated in our study, no grouping was made. We aimed to evaluate the effect of demographic characteristics, histopathological type, tumour location, type of operation, neoadjuvant therapy, presence of lymph node metastasis, the ratio of metastatic lymph node number to lymph node dissection number, N stage, T stage, presence of lymphovascular (LVI) and/or perineural invasion (PNI), tumour grade and the level of tumour markers and inflammatory parameters (platelet/lymphocyte ratio, lymphocyte/monocyte ratio, neutrophil/lymphocyte ratio, fibrinogen) on mean survival time by Kaplan-Meier. The univariate and multivariate hazard ratios were calculated by the Cox regression hazard model. Kaplan Meier test was used to calculate the mean survival curves. P<0.05 was deemed statistically significant.

**RESULTS**

**Demographic clinicopathologic characteristics**

128 patients included in the study were analysed retrospectively. 70 of the patients were male and 58 were female. The mean age is 57.70 years and the youngest patient is 24 years old. The tumour was mostly located in the antrum (38.3%) and corpus (39.1%), and a total gastrectomy was performed in 69 patients (53.9%). The operation was completed laparoscopically in 25 of the patients. Lymph node metastasis was present in 103 patients, with a mean lymph node metastasis of 1.51. The ratio of the number of metastatic lymph nodes to the number of lymph nodes dissected is 0.40 on average. 48.4% of the patients are in N3, and 75% of them are in the T4 stage. LVI is present in 67 patients and 92 patients are high grade. The mean value of carcino-embryogenic antigen (CEA) of the patients included in our study was 11.38 ng/ml, and the mean value of carcipher antigen 19-9 (Ca 19-9) was 44.51 ng/ml. In the distribution of inflammatory parameters, the platelet/lymphocyte ratio (PLR) average is 215.69, the lymphocyte/monocyte ratio (LMR) average is 4.34, the neutrophil/lymphocyte ratio (NLR) average is 5.74, and the fibrinogen value is 5.18 (Table 1).

**Univariate and multivariate analysis**

We performed Cox regression univariate analysis to investigate the effects of clinicopathological factors on mean survival follow-up in signet ring cell gastric cancer. First, we examined the hazard ratios of demographic parameters. As age increases, the mean survival follow-up period decreases. This relationship is also statistically significant (p=0.011). But HR is 1.021. Although it is statistically significant, the HR coefficient is very close to 1. In other words, although the increase in age statistically affects the mean survival follow-up period, this rate is quite low. This ratio loses its statistical value when the age of 65 is used as a basis for the WHO to distinguish between the elderly and young population (HR=1.414, 95% CI: 0.94-2.127, p≤0.097). In other words, there is no significant relationship between the mean survival time of patients over and under 65 years of age. Again, there was no statistically significant difference in the effect of gender HR, and the p-value was 0.658. In the relationship between tumour localization and HR, the mean survival time of patients with only limitis plastica was significantly lower (HR=4.173, p=0.021) when antral tumours were considered the reference. When we compare other

---

**Statistical analysis**

Data were analysed by using statistical package for the social sciences (SPSS) version 22.00. Univariate and multivariate death hazard ratios (HRs) were calculated by the Cox regression hazard model. Kaplan Meier test was used to calculate the mean survival curves. P<0.05 was deemed statistically significant.
localizations with the antrum, there is no significant difference. There is a significant difference between the mean survival and follow-up times of the surgeries performed with the laparoscopic or open technique. Mean survival follow-up for the open technique was lower than for laparoscopic procedures (HR=1.821, 95% CI: 1.03-3.129, p=0.039). There is a significant difference between the mean survival follow-up times of the patients according to the presence of LVI and PNI. The mean survival follow-up time of patients with positive LVI and PNI is lower than patients with negative LVI and PNI (HR=3.620, 95% CI: 2.306-5.684, p<0.001 and HR=2.058, 95% CI: 1.369-3.093, p<0.001). Lymph node metastasis is also an important variable that increases HR. The mean survival time of patients with lymph node metastases was significantly lower than those without lymph node metastasis (HR=3.945, 95% CI: 2.041-7.627, p<0.001). We confirmed this relationship with the analysis of the N phases. When we accepted N0 as a reference, we found that the mean survival and follow-up times of n2 and n3 patients were significantly lower. (HR=2.551 for N2, 95% CI: 1.167-5.578, p=0.019 and HR=8.062 for N3, 95% CI: 4.024-16.150, p<0.001). In the analysis of tumour T stages, when we accept the T1 stage as the reference value, the mean survival follow-up time of only T4 patients is significantly lower (HR=4.496, 95% CI: 1.943-10.404, p<0.001). There is no significant difference in the mean survival follow-up times of other T stages compared to T1. We did not find a significant relationship between the HRs of tumour markers and systemic inflammatory response parameters. However, we found a significant relationship between the increase in fibrinogen value and HR. Accordingly, an increase in the fibrinogen value leads to a significant decrease in the mean survival follow-up period of the patients (HR=1.312, 95% CI: 1.214-1.418, p<0.001). When we group the fibrinogen as high and normal according to the reference range, this rate increases even more. The mean survival time of patients with fibrinogen values above the reference value was 4.394 times lower than patients in the normal range (HR=4.394, 95% CI: 2.686-7.189, p<0.001). In the multivariate analysis, we found that no variable except fibrinogen made a significant contribution to the model. Although HR slightly decreased, fibrinogen also affected the mean survival follow-up in multivariate analysis (HR=2.286, 95% CI: 1.145-4.508, p<0.019) (Table 2).

### Survival analysis

We studied the mean survival analyses of the parameters whose HRs were found to be significant in Cox regression using the Kaplan Meier test. We found a significant correlation between the mean survival curves of tumour localization. The mean survival of patients with antrum localization was 56.61 months, while patients with linitis plastica were 6.33 months (p=0.03). There is a significant relationship between the mean survival curves of PNI and LVI. The mean survival of patients with PNI (+) and LVI (+) was lower than the patients with negative (31.88 versus 69.14 months, p<0.001 and 18.16 versus 86.42 months, p<0.001). The increase in the N stage and T stage is one of the important parameters affecting the average survival. Accordingly, the mean survival of patients with N3 is 15.65 months and 33.85 months for T4 patients. There is a significant difference in the mean survival analysis of fibrinogen, which contributes significantly to HR in both univariate and multivariate analyses. The mean survival for patients with fibrinogen values above the reference range was 22.69 months, and the mean survival for patients within the normal reference range was 101.76 months (p<0.001). The mean survival curves of the variables and analysis results are detailed in Figures 1-3.

| Variables | Mean±SD, n (%) |
|----------------|----------------|
| **Age (years)** | 57.70±14.11 (24-87) |
| **Gender** |  |
| Male | 70 (54.7) |
| Female | 58 (45.3) |
| **Location** |  |
| Antrum | 49 (38.3) |
| Corpus | 50 (39.1) |
| Fundus | 3 (2.3) |
| Cardia | 23 (18) |
| Linitis plastica | 3 (2.3) |
| **Neoadjuvant therapy** |  |
| Absent | 115 (89.8) |
| Present | 13 (10.2) |
| **Laparoscopic-open** |  |
| Laparoscopic | 25 (19.5) |
| Open | 103 (8.5) |
| **Operation** |  |
| Subtotal | 59 (46.1) |

*Continued.*

---

*Calcu S et al. Int Surg J. 2022 Aug 9 (8):1406-1415*
### Variables

| Mean±SD, n (%) | Total 69 (53.9) |
|----------------|------------------|
| **Metastatic lymph node status** | |
| Absent | 25 (19.5) |
| Present | 103 (80.5) |
| **Metastatic node** | 1.51±1.04 (0–6) |
| **Metastatic lymph node ratio** | 0.40±0.37 (0–1.65) |
| **N stage** | |
| N0 | 25 (19.5) |
| N1 | 17 (13.3) |
| N2 | 24 (18.8) |
| N3 | 62 (48.4) |
| **T stage** | |
| T1 | 16 (12.5) |
| T2 | 5 (3.9) |
| T3 | 11 (8.6) |
| T4 | 96 (75) |
| **LVI** | |
| Absent | 61 (47.7) |
| Present | 67 (52.3) |
| **PNI** | |
| Absent | 73 (57) |
| Present | 55 (43) |
| **Grade** | |
| Low | 20 (15.6) |
| Middle | 16 (12.5) |
| High | 92 (71.9) |
| **Carcinoembryonic antigen (ng/ml)** | 11.38±50.27 (0–438.62) |
| **Carbohydrate antigen 19-9 (ng/ml)** | 44.51±107.36 (0.6–949.9) |
| **Platelet/lymphocyte ratio (PLR)** | 215.69±185.29 (4.2–1670) |
| **Lymphocyte/monocytes ratio (LMR)** | 4.34±8.69 (0.26–82.8) |
| **Neutrophil/lymphocyte ratio (NLR)** | 5.74±8.65 (0.07–67) |
| **Fibrinogen (mg/dl)** | 5.18±2.53 (1.14–13.60) |
| **Length of hospital stay (days)** | 15.17±14.30 (5–160) |
| **Length of intensive care stay (days)** | 2.48±12.83 (0–146) |
| **Follow-up time (months)** | 37.89±44.47 (0–179) |
| **Survival** | |
| Live | 31 (24.2) |
| Death | 97 (75.8) |

---

**Figure 1:** The mean survival curves of the variables.
Table 2: Univariate and multivariate analysis of signet ring cell gastric carcinoma for overall survival.

| Characteristics                  | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR (95% CI)         | P value               | HR (95% CI)         | P value               |
| Age                              | 1.021 (1.005-1.037) | 0.011                 |                       |                       |
| Age (years)                      |                     |                       |                       |                       |
| <65                              |                     |                       |                       |                       |
| >65                              | 1.414 (0.94-2.127)  | 0.097                 |                       |                       |
| Gender                           |                     |                       |                       |                       |
| Male                             |                     |                       |                       |                       |
| Female                           | 1.110 (0.744-1.657) | 0.608                 |                       |                       |
| Location                         |                     |                       |                       |                       |
| Antrum                           |                     |                       |                       |                       |
| Corpus                           | 1.45 (0.927-2.282)  | 0.103                 |                       |                       |
| Fundus                           | 2.70 (0.816-8.946)  | 0.104                 |                       |                       |
| Cardia                           | 0.915 (0.492-1.701) | 0.778                 |                       |                       |
| Linitis plastica                 | 4.173 (1.239-14.052)| 0.021                 |                       |                       |
| Neoadjuvant therapy              |                     |                       |                       |                       |
| Absent                           | 1.241 (0.660-2.2334)| 0.503                 |                       |                       |
| Present                          |                     |                       |                       |                       |
| Laparoscopic/open                |                     |                       |                       |                       |
| Laparoscopic                     |                     |                       |                       |                       |
| Open                             | 1.821 (1.03-3.219)  | 0.039                 |                       |                       |
| Operation                        |                     |                       |                       |                       |
| Total                            | 0.504 (0.334-0.762) | 0.001                 |                       |                       |
| Subtotal                         |                     |                       |                       |                       |
| LVI                              | 3.620 (2.306-5.684) | <0.001                |                       |                       |
| Absent                           |                     |                       |                       |                       |
| Present                          | 2.058 (1.369-3.093) | 0.001                 |                       |                       |
| PNI                              |                     |                       |                       |                       |
| Absent                           | 3.945 (2.041-7.627) | <0.001                |                       |                       |
| Present                          |                     |                       |                       |                       |
| Grade                            |                     |                       |                       |                       |
| Low                              |                     |                       |                       |                       |
| Middle                           | 1.756 (0.712-4.326) | 0.221                 |                       |                       |
| High                             | 3.210 (1.601-6.435) | 0.001                 |                       |                       |
| Metastatic node status           | 3.020 (1.984-4.538) | <0.001                |                       |                       |
| Absent                           |                     |                       |                       |                       |
| Present                          | 3.020 (1.984-4.538) | <0.001                |                       |                       |
| N stage                          | 8.062 (4.024-16.150)| <0.001                |                       |                       |
| n0                               |                     |                       |                       |                       |
| n1                               | 1.507 (0.612-3.711) | 0.372                 |                       |                       |
| n2                               | 2.551 (1.167-5.578) | 0.019                 |                       |                       |
| n3                               | 8.062 (4.024-16.150)| <0.001                |                       |                       |
| T stage                          | 4.496 (1.943-10.404)| <0.001                |                       |                       |
| T1                               |                     |                       |                       |                       |
| T2                               | 0.529 (0.064-4.398) | 0.556                 |                       |                       |
| T3                               | 2.714 (0.935-7.878) | 0.066                 |                       |                       |
| T4                               | 4.496 (1.943-10.404)| <0.001                |                       |                       |
| Metastatic lymph node ratio      | 7.594 (4.517-12.765)| <0.001                |                       |                       |
| Carcinoembryonic antigen         | 1.003 (1.00-1.006)  | 0.073                 |                       |                       |
| Carbohydrate antigen 19-9        | 1.001 (1.00-1.002)  | 0.086                 |                       |                       |
| Platelet/lymphocyte ratio        | 1.00 (0.999-1.002)  | 0.391                 |                       |                       |
| Neutrophil/lymphocyte ratio      | 1.011 (0.987-1.036) | 0.373                 |                       |                       |
| Fibrinogen                       | 1.312 (1.214-1.418) | <0.001                |                       |                       |

Continued.
Characteristics | Univariate analysis | Multivariate analysis
--- | --- | ---
**Fibrinogen** | | |
Normal | | |
High | 4.394 (2.686-7.189) | <0.001 | 2.286 (1.145-4.568) | 0.019 |

Table 3: Mean overall survival time of LVI, operation type according to log rank analysis.

| Operation | Mean overall survival (month) | % 95 Cl | Log rank, p value |
| --- | --- | --- | --- |
| **TGI** | 34,903 | 21,973 | 47,833 | 0.001 |
| **SG** | 71,257 | 52,703 | 89,811 | <0.001 |
| **LVI** | | | |
| Absent | 86,429 | 67,082 | 105,775 | |
| Present | 18,168 | 12,676 | 23,660 | |

Figure 2: The mean survival curves of the variables.

Table 4: Mean overall survival time of T stage according to log rank analysis.

| T stage | Mean overall survival (month) | % 95 Cl | Log Rank, P value | Fibrinogen | Mean overall survival (month) | % 95 Cl | Log rank, P value |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **T 1** | 120,323 | 83,858 | 156,788 | Normal | 101,762 | 79,657 | 123,866 | <0.001 |
| **T 2** | 145,250 | 87,962 | 202,538 | High | 22,691 | 14,910 | 30,471 | <0.001 |
| **T 3** | 50,260 | 21,119 | 79,400 | | | | |
| **T 4** | 33,850 | 24,278 | 43,422 | | | | |

Table 5: Mean overall survival time of PNI and grade according to log rank analysis.

| Parameters | Mean overall survival (month) | % 95 Cl | Log rank, p value |
| --- | --- | --- | --- |
| **PNI** | | | |
| Absent | 69,147 | 52,165 | 86,130 | <0.001 |
| Present | 31,886 | 16,911 | 46,861 | |
| **Grade** | | | |
| Low | 105,830 | 71,321 | 140,339 | 0.001 |
| Middle | 67,817 | 34,600 | 101,035 | |
| High | 38,456 | 26,601 | 50,311 | |
Figure 3: The mean survival curves of the variables.

Table 6: Mean overall survival time of N stage.

| Parameters       | Mean overall survival (month) | % 95 CI | Log rank p value |
|------------------|-------------------------------|---------|------------------|
| **N stage**      |                               | Lower bound | Upper bound |            |
| N 0              | 99,782                        | 75,546  | 124,018          | <0.001     |
| N 1              | 95,887                        | 58,623  | 133,150          |            |
| N 2              | 63,896                        | 34,995  | 92,797           | <0.001     |
| N 3              | 15,658                        | 9,095   | 22,221           |            |
| **Metastatic node status** |                       |          |                  |
| Absent           | 99,782                        | 75,546  | 124,018          | >0.001     |
| Present          | 39,120                        | 27,595  | 50,646           |            |

DISCUSSION

Signet ring cell gastric carcinomas are a rare type of histological gastric cancer and are associated with poor overall survival compared to adenocarcinoma. Studies are reporting that it is a poor prognostic marker except for early-stage gastric cancer. Its incidence has been increasing in recent years and continues to be an important health problem for patients. However, there is a need to determine the optimal treatment strategy by avoiding unnecessary morbidity and mortality. Therefore, it is important to evaluate the clinicopathological features of signet-ring cell gastric carcinomas. In studies conducted in Asian and Western countries, it has been shown that signet ring cell gastric carcinomas are more common in young people, women, diffuse type, corpus, and distal stomach. Although studies evaluating prognostic factors in gastric cancer are widespread, the prognostic predictors of signet ring cell gastric carcinomas are largely undefined. The effect of age on prognosis is controversial. It has been reported that the prognosis is better in younger patients with low-grade signet-ring cell gastric carcinomas who
underwent radical surgery. In a population-based study based in China, age and advanced stage were reported to be poor prognostic risk factors for signet ring cell gastric cancer. Poor tolerance to radical surgery and chemotherapy due to poor performance status and comorbidities in elderly patients may be the reason for this. In our study, we observed that the mean survival time decreased with increasing age in signet-ring cell gastric cancers (HR=95%, p=0.011). However, when the patients were divided into two groups old (≥65 years) and young (<65 years) according to the WHO data, we could not find a significant relationship between the age of 65 and the mean survival time.

In addition, in our study, gender does not seem to be valuable in predicting the prognosis of signet ring cell gastric carcinomas, consistent with the findings of Chon et al. Contrary to studies showing that proximal gastric cancer has a worse prognosis than distally located ones, no statistically significant difference in survival was observed between tumors of the antrum and other regions in our study. The mean survival of patients with only limitis plastica Borrmann type IV was significantly lower (HR=4.173, p=0.021). In our study, the mean survival follow-up times were found to be longer in patients who underwent subtotal gastrectomy than in patients who underwent total gastrectomy (HR=0.504). We think that this is due to the higher incidence of complications due to total gastrectomy and delays in adjuvant treatment.

Signet ring cell gastric carcinoma has a similar prognosis to adenocarcinoma in advanced stages, while it is associated with a better survival rate in early gastric cancer. However, it has similar features to adenocarcinoma in terms of long-term survival in advanced stages. In addition, the histological grade is one of the other poor prognostic factors in gastric cancer. However, there are also studies reporting that histological grade is not a prognostic factor in signet-ring cell gastric carcinomas. In our study, we observed that high histological grade, depth of infiltration, and lymph node metastasis adversely affected the mean survival.

In general, lymphovascular and perineural invasion in gastric cancer is an unfavorable prognostic indicator independent of the stage. Although specific studies for signet ring cell gastric carcinomas are insufficient in the literature, lymphovascular and perineural invasion are unquestionably poor prognostic factors for this histological subtype. In our study, the mean survival of patients with positive lymphovascular and perineural invasion was found to be significantly lower.

When we examined the effects of tumor markers, inflammatory response parameters, and hematological parameters that we routinely studied preoperatively, as well as the prognostic factors we could obtain with postoperative pathological results, we observed an inverse relationship between preoperative plasma fibrinogen levels and mean survival follow-up time. Considering the studies reporting that high plasma fibrinogen levels are associated with adjacent organ involvement, lymph node metastasis, liver metastasis, and poor overall survival in gastric cancer, this result was a significant finding for our study.

The benefit of neoadjuvant chemotherapy in signet ring cell gastric cancer is controversial. Although the advantages of chemotherapy in gastric cancer were emphasized in the MAGIC study, the benefits of neoadjuvant chemotherapy in signet-ring cell gastric cancers are controversial. In a retrospective study evaluating 924 signet ring cell gastric cancers, it was reported that perioperative chemotherapy did not affect survival, and neoadjuvant chemotherapy was associated with shorter survival compared to surgery alone. Similar results were obtained in different neoadjuvant chemotherapy studies. Conversely, there are studies indicating that neoadjuvant chemotherapy is associated with better outcomes in signet ring cell gastric cancer. The negative effects of neoadjuvant therapy on survival may be due to postoperative morbidity due to drug toxicity. However, there is a risk of tumor progression during treatment.

In our study, we observed that neoadjuvant chemotherapy did not affect survival (HR=1.24,1 p=0.503). Despite conflicting data in the literature, advanced signet ring cell gastric cancers can be treated with neoadjuvant chemotherapy or direct surgery. More studies are needed to evaluate the effectiveness of these two approaches. Advanced signet ring cell gastric carcinoma has a worse prognosis than other histological types. Metastases to lymph nodes and peritoneum are common at the time of diagnosis. There is no consensus in the literature on the preferred surgical method and the extent of lymph node dissection. In a recent study by Morkavuk et al, they compared D1 and D1+ lymph node dissection in signet-ring cell gastric cancers and did not report a significant difference in survival between the two methods. However, it is widely accepted that survival rates increase with D2 lymphadenectomy. Since we applied D2 dissection to all patients in our study, we could not find the opportunity to compare D1 and D2 lymphadenectomy. However, we observed that the mean survival follow-up times were shorter in N1 and N2 patients. We think that standard D2 lymphadenectomy may improve prognosis in signet-ring cell gastric cancers, reduce the risk of tumor recurrence and metastasis, and prolong survival.

Radical gastrectomy is the gold standard in the treatment of gastric cancer, and the current literature supports minimally invasive surgery. On the other hand, in advanced stage signet ring cell gastric cancer, the data in the literature are conflicting and there is no consensus on the surgical method. In the CLASS-01 study, in which 15% of the laparoscopic group consisted of signet-ring cell gastric cancers, similar results were obtained in terms of 3-year disease-free survival between the laparoscopic and open groups in patients who underwent distal gastrectomy.
and D2 lymph node dissection. In our study, the average survival time was found to be longer in patients who underwent laparoscopic surgery compared to conventional surgery. The reason for this may be that we preferred laparoscopy in the selected patient group with a low clinical stage when we started laparoscopic surgery. With the increase in our experience in laparoscopic surgery and technological developments in minimally invasive surgery, we now prefer laparoscopy in our current practice, also in locally advanced stages.

Our study has some limitations that may affect the results. First of all, the most important limitations of our study are that it is retrospective, single-centered, and the number of patients is small. Since patients with distant metastases were not included in the study, our knowledge of all signet ring cell gastric cancers is limited. In addition, the inhomogeneity of the adjuvant treatments of the patients, the lack of data on tumor size, distant metastasis, and recurrence time can be counted among the limitations. However, we think that this study is valuable, given the lack of data in the literature on prognostic factors in signet-ring cell gastric cancers.

CONCLUSION

In conclusion, we investigated the clinicopathological features of nonmetastatic signet ring cell gastric carcinomas and identified predictors of long survival. Age, lymphovascular and perineural invasion, open surgery, higher tumor infiltration, and lymph node involvement were independent predictors of shorter survival times in nonmetastatic signet ring cell gastric cancers. Our study has important implications for the clinical management of signet ring cell gastric carcinomas. In the future, more studies are needed to develop individual strategies for the treatment and management of signet ring cell gastric cancers.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer J Clin. 2018;68(6):394–424.
2. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241(1):27-39.
3. Benesch MGK, Mathieson A. Epidemiology of Signet Ring Cell Adenocarcinomas. Cancers (Basel). 2020;12(6):1544.
4. Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21(40):11428-38.
5. Li Y, Zhu Z, Ma F, Xue L, Tian Y. Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges. Cancer Manag Res. 2020;12:7973-81.
6. Fléjou JF. Classification OMS 2010 des tumeurs digestives: la quatrième édition [WHO Classification of digestive tumors: the fourth edition]. Ann Pathol. 2011;31(5):27-31.
7. Chen TH, Lin WR, Lee C, Chiu CT, Hsu JT, Yeh TS, et al. Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and GALNT14 Genotype. J Cancer. 2018;9(19):3540-7.
8. In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol. 2017;24(12):3683-91.
9. Guo J, Yu J, Xu Z, Sun X, Zheng J. The role of surgery in patients aged 85 years or older with resectable gastric cancer: a propensity score matching analysis of the SEER database. Scand J Gastroenterol. 2020;55(6):694-700.
10. Pyo JH, Lee H, Min BH, Lee JH, Choi MG, Lee JH, et al. Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. J Gastroenterol. 2017;52(5):594-601.
11. Cui J, Liang H, Deng J, Ding X, Wang X, Zhang L, Liang Y, Jiang N. Clinicopathological features and prognostic analysis of patients with signet ring cell gastric carcinoma. Zhonghua Zhong Liu Za Zhi. 2015;37(5):367-70.
12. Lu M, Yang Z, Feng Q, Yu M, Zhang Y, Yao C, Shen L, Tang J. The characteristics and prognostic value of signet ring cell histology in gastric cancer: A retrospective cohort study of 2199 consecutive patients. Medicine (Baltimore). 2016;95(27):e4052.
13. Guo S, Shang MY, Dong Z, Zhang J, Wang Y, Zheng ZC, Zhao Y. Clinicopathological features and prognostic analysis of signet ring cell gastric carcinoma: a population-based study. Trans Cancer Res. 2019;8:1918-30.
14. Suh DD, Oh ST, Yook JH, Kim BS, Kim BS. Differences in the prognosis of early gastric cancer according to sex and age. Therap Adv Gastroenterol. 2017;10(2):219-29.
15. Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, et al. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. Ann Surg. 2017;265(5):946-953.
16. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, et al. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005;23(13):3094-103.
17. Jiang CG, Wang ZN, Sun Z, Liu FN, Yu M, Xu HM. Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: results from a Chinese mono-institutional study. J Surg Oncol. 2011;103(7):700-3.

18. Zhang S, Liu Y, Jiao Z, Li Z, Wang J, Li C, Qu X, Xu L. Development and Validation of a Prognostic Nomogram for Gastric Signet Ring Cell Carcinoma: A Multicenter Population-Based Study. Front Oncol. 2021;11:603031.

19. Deng J, You Q, Gao Y, Yu Q, Zhao P, Zheng Y, Fang W, Xu N, Teng L. Prognostic value of perineural invasion in gastric cancer: a systematic review and meta-analysis. PLoS One. 2014;9(2):e88907.

20. Lee SE, Lee JH, Ryu KW, Nam BH, Cho SJ, Lee JY, Kim CG, Choi JJ, Kook MC, Park SR, Kim YW. Preoperative plasma fibrinogen level is a useful predictor of adjacent organ involvement in patients with advanced gastric cancer. J Gastric Cancer. 2012;12(2):81-7.

21. Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017;3(9):1197-203.

22. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C; FREGAT working group - FRENCH. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg. 2011;254(5):684-93.

23. Li Y, Ma FH, Xue LY, Tian YT. Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study. World J Gastroenterol. 2020;26(8):818-27.

24. Heger U, Sisic L, Nienhüser H, Blank S, Hinz U, Haag GM, Ott K, Ulrich A, Büchler MW, Schmidt T. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas. Ann Surg Oncol. 2018;25(8):2418-27.

25. Chung JW, Jung HY, Choi KD, Song HJ, Lee GH, Jang SJ, Park YS, Youk JH, Oh ST, Kim BS, Kim JH. Extended indication of endoscopic resection for mucosal early gastric cancer: analysis of a single center experience. J Gastroenterol Hepatol. 2011;26(5):884-7.

26. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1-21.

27. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev. 2000;26(4):243-55.

28. Morkavuk ŞB, Çulcu S, Tez M, Ünal AE. The efficiency of D1(+) lymphadenectomy in signet ring cell carcinoma: comparison of postoperative early and late outcomes between standard lymphadenectomy and D1(+) lymphadenectomy. Libyan J Med. 2021;16(1):1973761.

29. Santoro R, Ettorre GM, Santoro E. Subtotal gastrectomy for gastric cancer. World J Gastroenterol. 2014;20(38):13667-80.

30. Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, et al. Effect of Laparoscopic vs Open Distal Gastroctomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. JAMA. 2019;321(20):1983-92.

Cite this article as: Çulcu S, Tamam S, Ünal AE. Factors affecting prognosis in signet ring cell gastric cancers with expanded lymph node dissection; high volume centre experience. Int Surg J 2022;9:1406-15.